1-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole → HCID 72545353, 화합물

HRID 73792

반응식

HRID 73792 반응식
Br[C:2]1[C:3]([N:22]2[CH2:26][CH2:25][C@@H:24]([OH:27])[CH2:23]2)=[N:4][CH:5]=[C:6]([CH:21]=1)[C:7]([NH:9][C:10]1[CH:15]=[CH:14][C:13]([O:16][C:17]([Cl:20])([F:19])[F:18])=[CH:12][CH:11]=1)=[O:8].[CH3:28][N:29]1[C:33](B2OC(C)(C)C(C)(C)O2)=[CH:32][CH:31]=[N:30]1>>[Cl:20][C:17]([F:19])([F:18])[O:16][C:13]1[CH:14]=[CH:15][C:10]([NH:9][C:7](=[O:8])[C:6]2[CH:21]=[C:2]([C:33]3[N:29]([CH3:28])[N:30]=[CH:31][CH:32]=3)[C:3]([N:22]3[CH2:26][CH2:25][C@@H:24]([OH:27])[CH2:23]3)=[N:4][CH:5]=2)=[CH:11][CH:12]=1

참가 물질

3

반응물 2

HCID 49129081-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazoleHCID 72545856(R)-5-Bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)nicotinamide

생성물 1

HCID 72545353HCID 72545353, 화합물

실험 절차

The title compound was prepared in an analogous fashion to that described in Stage 2.1 using (R)-5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)nicotinamide (Stage 9.2) and 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole to afford a white powder. HPLC (Condition 4) tR=5.25 min, UPLC-MS (Condition 3) tR0.98 min, m/z=464.1 [M+H]+; 1H-NMR (400 MHz, DMSO-d6) δ ppm 1.65-1.89 (m, 2H) 2.87-3.00 (m, 1H) 3.09-3.29 (m, 3H) 3.59 (s, 3H) 4.19 (br. s, 1H) 4.87 (d, J=3.13 Hz, 1H) 6.39 (s, 1H) 7.27-7.36 (m, 2H) 7.50 (dd, J=1.76, 0.98 Hz, 1H) 7.78-7.88 (m, 2H) 8.00 (d, J=2.35 Hz, 1H) 8.78 (dd, J=2.35, 1.17 Hz, 1H) 10.15 (s, 1H).

후처리

  1. customto afford a white powder

출처 및 근거

ORD 기록
ord-f637c324a78543e99e7d2f458b6c07ba
출처 데이터셋
uspto-grants-2014_09
특허 번호
US08829195B2

연결된 노트

불러오는 중…